fbpx

Investigational RSV Antiviral Meets Primary Endpoints in Small Adult Human Challenge Trial


Image credit: Gustavo Fring, Pexels

Watertown, Mass-based Encanta Pharmaceuticals announced positive results from its phase 2a human challenge study demonstrating its investigational antiviral, EDP-323, achieved an 85-87% reduction in viral load area under the curve (AUC) by qRT-PCR (p<0.0001); a 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001); and a 66-78% reduction of total clinical symptoms score AUC (p<0.0001) compared to placebo.

EDP-323 was given to healthy adults infected with RSV, and was generally safe and well-tolerated the company said. EDP-323 is a novel L-protein inhibitor in development as a once-daily oral treatment for RSV.

“We are excited about these impressive data that demonstrate a rapid and sustained reduction in viral load,” Encanta Chief Medical Officer Scott Rottinghaus, MD, said in a statement. “These results are among the strongest ever reported in an RSV challenge study, raising the high bar set by zelicapavir [the company’s investigational N-protein inhibitorin Phase 2 development]. The significant antiviral activity and symptom alleviation observed in this study highlight EDP-323’s potential as a safe, highly effective, direct-acting antiviral for the treatment of RSV.”

Encanta is a clinical-stage biotechnology company that develops small molecule drugs for virology and immunology indications, and it received a Fast Track designation from the FDA for EDP-323.

What You Need to Know

Encanta Pharmaceuticals’ investigational antiviral, EDP-323, showed significant efficacy in reducing RSV viral load.

EDP-323 was well-tolerated and generally safe when administered to healthy adults infected with RSV.

Encanta is developing EDP-323 as part of a broader strategy to address respiratory infections, with both L-protein and N-protein inhibitors in phase 2 trials.

Trial Specifics

The trial was a randomized, double-blind, placebo-controlled, human challenge study of 142 healthy adult participants inoculated with RSV. Randomized participants (n=141) received either a once-daily (QD) 600 mg dose of EDP-323 for five days [high dose, n=47], a single 600 mg loading dose on day one followed by a 200 mg once-daily (QD) dose of EDP-323 for four days [low dose, n=47], or placebo for five days [n=47]. The intent-to-treat-infected population (ITT-I) was defined as all randomized participants receiving challenge virus and at least one dose of study drug with confirmed RSV infection.

In a previous phase 1 study, EDP-323 was found to be generally safe and well-tolerated in healthy subjects up to 800 mg for up to seven days, with a pharmacokinetic profile supporting once-daily dosing and all doses achieving target exposures.

In addition, EDP-323 is also supported by in vitro data demonstrating a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells infected with RSV A and B, and across a range of RSV clinical isolates and various cell types. In a mouse model of RSV infection, EDP-323 treatment was associated with dose-dependent decreases in viral load in the lung, reductions in lung immunopathology and decreases in pro-inflammatory cytokines, including IFNγ, TNFα, and IL1β.

“These EDP-323 results represent a meaningful advancement toward achieving our longstanding goal of developing new medicines to treat respiratory infections such as RSV, as there remains a substantial need for safe and effective oral treatments. “Enanta has the leading portfolio of potent RSV replication inhibitors, with EDP-323, our L-protein inhibitor, and zelicapavir, our N-protein inhibitor, both in phase 2 development,” Encanta CEO Jay R. Luly, PhD, said in a statement. “These distinct mechanisms have the potential to be developed as once-daily single agents or in combination for specific patient populations.”

Reference
1.Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV). Encanta press release. September 26, 2024. Accessed October 2, 2024.
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-topline-results-edp



Source link

Daily Dose of Insights

Get a daily infusion of knowledge with our latest blog updates.

We don’t spam! Read our privacy policy for more info.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Cranberry Pecan Cheese Ball | The Recipe Critic

This website may contain affiliate links and advertising so that we can provide recipes to you. Read...

Reducing Long COVID Symptoms by Way of Vaccination

Image credit: myskin, Adobe StockThis article originally appeared on our sister site, Drug Topics.Receiving a COVID-19 vaccine...

Brown Sugar Pineapple Glazed Ham

This website may contain affiliate links and advertising so that we can provide recipes to you. Read...

Early Geriatric Assessment Improves Outcomes for Older Patients With C difficile Infection

C diff infectionImage credits: UnsplashA recent randomized trial published in The Lancet found that early comprehensive geriatric...
Optimized by Optimole